Osimertinib, a third‐generation EGFR–TKI, is extensively used to treat NSCLCs that harbor the T790M mutation and is an effective sequential therapy for EGFR‐mutated NSCLC patients with an acquired T790M mutation after first‐ or second‐generation EGFR–TKI treatment.39 Here, EGFR is linked to non-small cell lung carcinoma.